A5041768679- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Gallbladder and Bile Duct Disorders
- Cancer Genomics and Diagnostics
- Cancer Mechanisms and Therapy
- Cancer Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Inflammatory Biomarkers in Disease Prognosis
- Pancreatitis Pathology and Treatment
- Brain Metastases and Treatment
- Cancer, Lipids, and Metabolism
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Cancer, Hypoxia, and Metabolism
- Genetic factors in colorectal cancer
- Gyrotron and Vacuum Electronics Research
- Pediatric Hepatobiliary Diseases and Treatments
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Gestational Trophoblastic Disease Studies
The Christie NHS Foundation Trust
2016-2025
University of Manchester
2016-2025
Cancer Research UK Manchester Institute
2016-2024
Monash University
2023-2024
The Christie Hospital
2015-2023
Manchester University NHS Foundation Trust
2022-2023
Australian and New Zealand Intensive Care Society
2023
Princess Margaret Cancer Centre
2012-2022
National Health Service
2015-2022
University Hospital Galway
2021
BACKGROUND: Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years. The TOPAZ-1 trial evaluated durvalumab chemotherapy patients cancer. METHODS: In this double-blind, placebo-controlled, phase 3 study, we randomly assigned previously untreated unresectable or metastatic recurrent disease 1:1 to receive placebo in combination gemcitabine cisplatin up eight cycles, followed...
The incidence of intrahepatic cholangiocarcinoma (iCCA) is increasing. aim the study was to provide reference survival data for patients with advanced iCCA treated first-line cisplatin-gemcitabine chemotherapy (current standard care). Individual from recruited into prospective, random assignment Advanced Biliary Tract Cancer (ABC)-01, -02, and -03 studies were retrieved. prevalence liver-only also assessed. Survival analysis performed using univariate multivariable Cox regression. All...
BACKGROUND The neutrophil‐to‐lymphocyte ratio (NLR), a marker of inflammation, has been reported to be poor prognostic indicator in prostate cancer. Here we explore the use NLR establish simple score for men with metastatic castration‐resistant cancer (mCRPC) treated docetaxel. METHODS: In training cohort, and other known variables were evaluated among cohort chemotherapy‐naïve patients thrice‐weekly docetaxel at Princess Margaret Cancer Centre. Significant identified by univariable Cox...
Background: Molecular profiling is becoming increasingly relevant in the management of patients with advanced cancer; to identify targetable aberrations and prognostic markers enable a precision medicine strategy. Methods: Eligible were those diagnosed biliary tract cancer (BTC) including intrahepatic (iCCA) extrahepatic cholangiocarcinoma (eCCA), gallbladder (GBC), ampullary carcinoma (Amp) who underwent molecular between April 2017 June 2020 based on analysis either tumour samples...
Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with complex microenvironment. Dichotomous tumour-promoting and -restrictive roles have been ascribed to the tumour microenvironment, however effects of individual stromal subsets remain incompletely characterised. Here, we describe how heterocellular Oncostatin M (OSM) - Receptor (OSMR) signalling reprograms fibroblasts, regulates growth metastasis. Macrophage-secreted OSM stimulates inflammatory gene expression in...
Glioblastoma, the most common primary brain tumor, has few available therapies providing significant improvement in survival. Molecular signatures associated with tumor aggressiveness as well disease progression and their relation to differences signaling pathways implicated gliomagenesis have recently been described. A number of biomarkers which potential diagnosis, prognosis prediction response therapy identified along imaging modalities could contribute clinical management GBM. including...
Evidence suggests hyperglycemia is associated with worse outcomes in glioblastoma (GB). This study aims to confirm the association between glycemia during radiotherapy (RT) and temozolomide (TMZ) treatment overall survival (OS) patients newly diagnosed GB. retrospective included GB treated RT TMZ from 2004 2011, randomly divided into independent derivation validation datasets. Time-weighted mean (TWM) glucose dexamethasone dose were collected start of 4 weeks after RT. Univariate (UVA)...